A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

NCT06118515 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

NIH

Sponsor class

Conditions

Congenital Cytomegalovirus Infection

Interventions

DRUG: Letermovir

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)